In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices

Linda K. Hansen, Mary Brown, David Johnson, Donald F. Palme, Charles Love, Rabih Darouiche

Research output: Contribution to journalArticle

Abstract

Background: Device-related infections represent a significant clinical challenge. Once established, these infections prove difficult to treat with existing antibiotic regimens, compromising the health of device recipients, and usually requiring surgical intervention to resolve. Objective: The purpose of this study was to determine the efficacy of the AIGIS RX™ antibacterial envelope (TyRx Pharma, Inc., Monmouth Junction, NJ, USA) designed to reduce device-related infections by incorporating minocycline and rifampin in a controlled release polymer. Methods: An infection was established in a rabbit model by creating bilateral subcutaneous implant pockets, into which a pacing device with or without AIGIS RX™ was placed. The incisions were closed, and a defined dose of bacteria was infused into each implant pocket. After 7 days, devices were explanted and sampled for viable bacteria by swabbing and sonication. Results: Initial studies evaluated the ability of the AIGIS RX pouch to reduce Staphylococcus epidermidis (S. epi) infection in this model using clinical and quantitative microbial endpoints. Results demonstrate S. epi infection in all control samples, while no pathogens were recovered from samples with the AIGIS RX™ pouch. Systemic antibiotic levels were undetectable. Additional studies tested the efficacy of the AIGIS RX™ pouch with additional bacterial strains, Staphylococcus capitis, Escherichia coli, and Acinetobacter Baumannii. In each case, the device and implant pocket with the AIGIS RX™ pouch was free of any signs of infection. An assessment of biofilm produced by Acinetobacter demonstrated the elimination of biofilm formation on the implanted device. Conclusion: These results demonstrate that in this animal model, the AIGIS RX™ device reduces the risk for infection of viable pathogens within implant pockets. (PACE 2009; 32:898-907)

Original languageEnglish (US)
Pages (from-to)898-907
Number of pages10
JournalPACE - Pacing and Clinical Electrophysiology
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Equipment and Supplies
Infection
Staphylococcus epidermidis
Biofilms
Anti-Bacterial Agents
Bacteria
Acinetobacter baumannii
Minocycline
Acinetobacter
Sonication
Rifampin
Staphylococcus
Polymers
Animal Models
Escherichia coli
Rabbits
Health

Keywords

  • Device infection
  • Pacemaker

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices. / Hansen, Linda K.; Brown, Mary; Johnson, David; Palme, Donald F.; Love, Charles; Darouiche, Rabih.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 32, No. 7, 01.07.2009, p. 898-907.

Research output: Contribution to journalArticle

Hansen, Linda K. ; Brown, Mary ; Johnson, David ; Palme, Donald F. ; Love, Charles ; Darouiche, Rabih. / In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices. In: PACE - Pacing and Clinical Electrophysiology. 2009 ; Vol. 32, No. 7. pp. 898-907.
@article{0a3fd31e3a6c459780d033412cdf21b3,
title = "In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices",
abstract = "Background: Device-related infections represent a significant clinical challenge. Once established, these infections prove difficult to treat with existing antibiotic regimens, compromising the health of device recipients, and usually requiring surgical intervention to resolve. Objective: The purpose of this study was to determine the efficacy of the AIGIS RX™ antibacterial envelope (TyRx Pharma, Inc., Monmouth Junction, NJ, USA) designed to reduce device-related infections by incorporating minocycline and rifampin in a controlled release polymer. Methods: An infection was established in a rabbit model by creating bilateral subcutaneous implant pockets, into which a pacing device with or without AIGIS RX™ was placed. The incisions were closed, and a defined dose of bacteria was infused into each implant pocket. After 7 days, devices were explanted and sampled for viable bacteria by swabbing and sonication. Results: Initial studies evaluated the ability of the AIGIS RX pouch to reduce Staphylococcus epidermidis (S. epi) infection in this model using clinical and quantitative microbial endpoints. Results demonstrate S. epi infection in all control samples, while no pathogens were recovered from samples with the AIGIS RX™ pouch. Systemic antibiotic levels were undetectable. Additional studies tested the efficacy of the AIGIS RX™ pouch with additional bacterial strains, Staphylococcus capitis, Escherichia coli, and Acinetobacter Baumannii. In each case, the device and implant pocket with the AIGIS RX™ pouch was free of any signs of infection. An assessment of biofilm produced by Acinetobacter demonstrated the elimination of biofilm formation on the implanted device. Conclusion: These results demonstrate that in this animal model, the AIGIS RX™ device reduces the risk for infection of viable pathogens within implant pockets. (PACE 2009; 32:898-907)",
keywords = "Device infection, Pacemaker",
author = "Hansen, {Linda K.} and Mary Brown and David Johnson and Palme, {Donald F.} and Charles Love and Rabih Darouiche",
year = "2009",
month = "7",
day = "1",
doi = "10.1111/j.1540-8159.2009.02406.x",
language = "English (US)",
volume = "32",
pages = "898--907",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices

AU - Hansen, Linda K.

AU - Brown, Mary

AU - Johnson, David

AU - Palme, Donald F.

AU - Love, Charles

AU - Darouiche, Rabih

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Background: Device-related infections represent a significant clinical challenge. Once established, these infections prove difficult to treat with existing antibiotic regimens, compromising the health of device recipients, and usually requiring surgical intervention to resolve. Objective: The purpose of this study was to determine the efficacy of the AIGIS RX™ antibacterial envelope (TyRx Pharma, Inc., Monmouth Junction, NJ, USA) designed to reduce device-related infections by incorporating minocycline and rifampin in a controlled release polymer. Methods: An infection was established in a rabbit model by creating bilateral subcutaneous implant pockets, into which a pacing device with or without AIGIS RX™ was placed. The incisions were closed, and a defined dose of bacteria was infused into each implant pocket. After 7 days, devices were explanted and sampled for viable bacteria by swabbing and sonication. Results: Initial studies evaluated the ability of the AIGIS RX pouch to reduce Staphylococcus epidermidis (S. epi) infection in this model using clinical and quantitative microbial endpoints. Results demonstrate S. epi infection in all control samples, while no pathogens were recovered from samples with the AIGIS RX™ pouch. Systemic antibiotic levels were undetectable. Additional studies tested the efficacy of the AIGIS RX™ pouch with additional bacterial strains, Staphylococcus capitis, Escherichia coli, and Acinetobacter Baumannii. In each case, the device and implant pocket with the AIGIS RX™ pouch was free of any signs of infection. An assessment of biofilm produced by Acinetobacter demonstrated the elimination of biofilm formation on the implanted device. Conclusion: These results demonstrate that in this animal model, the AIGIS RX™ device reduces the risk for infection of viable pathogens within implant pockets. (PACE 2009; 32:898-907)

AB - Background: Device-related infections represent a significant clinical challenge. Once established, these infections prove difficult to treat with existing antibiotic regimens, compromising the health of device recipients, and usually requiring surgical intervention to resolve. Objective: The purpose of this study was to determine the efficacy of the AIGIS RX™ antibacterial envelope (TyRx Pharma, Inc., Monmouth Junction, NJ, USA) designed to reduce device-related infections by incorporating minocycline and rifampin in a controlled release polymer. Methods: An infection was established in a rabbit model by creating bilateral subcutaneous implant pockets, into which a pacing device with or without AIGIS RX™ was placed. The incisions were closed, and a defined dose of bacteria was infused into each implant pocket. After 7 days, devices were explanted and sampled for viable bacteria by swabbing and sonication. Results: Initial studies evaluated the ability of the AIGIS RX pouch to reduce Staphylococcus epidermidis (S. epi) infection in this model using clinical and quantitative microbial endpoints. Results demonstrate S. epi infection in all control samples, while no pathogens were recovered from samples with the AIGIS RX™ pouch. Systemic antibiotic levels were undetectable. Additional studies tested the efficacy of the AIGIS RX™ pouch with additional bacterial strains, Staphylococcus capitis, Escherichia coli, and Acinetobacter Baumannii. In each case, the device and implant pocket with the AIGIS RX™ pouch was free of any signs of infection. An assessment of biofilm produced by Acinetobacter demonstrated the elimination of biofilm formation on the implanted device. Conclusion: These results demonstrate that in this animal model, the AIGIS RX™ device reduces the risk for infection of viable pathogens within implant pockets. (PACE 2009; 32:898-907)

KW - Device infection

KW - Pacemaker

UR - http://www.scopus.com/inward/record.url?scp=67650669013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650669013&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8159.2009.02406.x

DO - 10.1111/j.1540-8159.2009.02406.x

M3 - Article

C2 - 19572866

AN - SCOPUS:67650669013

VL - 32

SP - 898

EP - 907

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 7

ER -